Roxadustat Inhibits Osteoclast Differentiation and Function by Disrupting Cell Cycle Exit
International Journal of Molecular Sciences · 18.06.2026 · 27 (12) · 5506
DOI: 10.3390/ijms27125506 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.06.2026. Verfasst von Afang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Peking University People's Hospital, Beijing 100044, China. Hauptthemen laut MEDLINE: Osteoclasts, Isoquinolines, Cell Differentiation, Glycine. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, National Key Research and Development Program of China.
Abstract (Originalsprache)
Bone remodeling relies on a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, promotes osteoblast differentiation but its effects on osteoclasts remain unclear. This study investigated roxadustat’s impact on osteoclast differentiation and function in vitro using primary murine bone marrow-derived mononuclear cells differentiated with M-CSF and RANKL. Cell viability, TRAP staining, bone resorption assays, RNA-seq, flow cytometry, immunofluorescence, Western blot for p27, and rescue experiments with the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor abemaciclib were performed. Roxadustat suppressed osteoclast differentiation and resorption without cytotoxicity in a concentration-dependent manner. RNA-seq revealed enrichment of cell cycle pathways; although differentiation was inhibited, roxadustat paradoxically promoted osteoclast precursor proliferation, evidenced by increased Ki67 and decreased p27 expression. The inhibitory effects on osteoclastogenesis and resorption were partially reversed by abemaciclib. Given that terminal differentiation typically requires cell cycle exit, these findings suggest that roxadustat may inhibit osteoclast differentiation at least in part by disrupting this process, promoting precursor proliferation, and downregulating p27. Together with its known anabolic effects on osteoblasts, roxadustat might have dual therapeutic potential for bone disorders with renal anemia, such as osteoporosis in chronic kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Peking University People's Hospital, Beijing 100044, China.
- Department of Trauma and Orthopedics, Peking University People's Hospital, Beijing 100044, China.
ORCID-Profile: Afang Li, Yaoxian Liang, Xinju Zhao
Förderung
- Natural Science Foundation of Beijing Municipality
- National Key Research and Development Program of China
Zitieren
APA
Li, A., Zuo, L., Li, L., Gan, L., Wang, M., Liang, Y., Li, Q., & Zhao, X. (2026). Roxadustat Inhibits Osteoclast Differentiation and Function by Disrupting Cell Cycle Exit. International Journal of Molecular Sciences, 27(12), 5506. https://doi.org/10.3390/ijms27125506
Vancouver
Li A, Zuo L, Li L, Gan L, Wang M, Liang Y, et al. Roxadustat Inhibits Osteoclast Differentiation and Function by Disrupting Cell Cycle Exit. International Journal of Molecular Sciences. 2026;27(12):5506. doi:10.3390/ijms27125506
BibTeX
@article{Li2026,
author = {Li, Afang and Zuo, Li and Li, Luyao and Gan, Liangying and Wang, Mi and Liang, Yaoxian and Li, Qicheng and Zhao, Xinju},
title = {Roxadustat Inhibits Osteoclast Differentiation and Function by Disrupting Cell Cycle Exit},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5506},
doi = {10.3390/ijms27125506}
}
EUVIMED